Emerging Treatment Strategies in Pancreatic Cancer.
| Autor: | Trunk A; From the Department of Internal Medicine, University of Utah., Miotke L; From the Department of Internal Medicine, University of Utah., Nevala-Plagemann C; Division of Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT., Verdaguer H; Division of Medical Oncology, Vall d'Hebrón University Hospital, Vall d'Hebrón Institute of Oncology, Barcelona, Spain., Macarulla T; Division of Medical Oncology, Vall d'Hebrón University Hospital, Vall d'Hebrón Institute of Oncology, Barcelona, Spain., Garrido-Laguna I; Division of Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Pancreas [Pancreas] 2021 Jul 01; Vol. 50 (6), pp. 773-787. |
| DOI: | 10.1097/MPA.0000000000001845 |
| Abstrakt: | Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the main causes of cancer death in well-developed countries. Therapeutic advances in PDAC to date have been modest. Recent progress to understand the molecular landscape of the disease has opened new treatment opportunities for a small subset of patients, frequently those with KRAS wild-type disease. Novel treatment strategies in PDAC include, among others, the use of nanotechnology and metabolic reprogramming. In addition, new strategies are being investigated, which are designed to overcome the resistance to checkpoint inhibitors, targeting DNA repair pathways including mismatch repair, increasing antigen presentation through the use of vaccines, targeting various signaling pathways, and reprogramming the tumor microenvironment. Here, we review the landscape of PDAC treatment strategies and some of these new agents. Competing Interests: The authors declare no conflict of interest. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|